Gastric antral vascular ectasia: the evolution of therapeutic modalities

Gastric Antral Vascular Ectasia (GAVE) may be an enigmatic source of non-variceal upper GI bleeding associated with various systemic diseases such as connective tissue disorders, liver disease, and chronic renal failure. Successful treatment of GAVE continues to be a challenge and has evolved through the years. Currently, given the rapid response, safety, and efficacy, endoscopic ablative modalities have largely usurped medical treatments as first-line therapy, particularly using argon plasma coagulation. However, other newer ablative modalities such as radiofrequency ablation, cryotherapy, and band ligations are promising. This paper is an overview of GAVE and its various endoscopic and medical therapies.

• References

• 1 Rider JA, Klotz AP, Kirsner JB. Gastritis with veno-capillary ectasia as a source of massive gastric hemorrhage. Gastroenterology 1953; 24: 118-123
• 2 Jabbari M, Cherry R, Lough JO et al. Gastric antral vascular ectasia: the watermelon stomach. Gastroenterology 1984; 87: 1165-1170
• 3 Stotzer PO, Willén R, Kilander AF. Watermelon stomach: not only an antral disease. Gastrointest Endosc 2002; 55: 897-900
• 4 Gilliam III JH, Geisinger KR, Wu WC et al. Endoscopic biopsy is diagnostic in gastric antral vascular ectasia. The “watermelon stomach”. Dig Dis Sci 1989; 34: 885-888
• 5 Payen JL, Calès P, Voigt JJ et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995; 108: 138-144
• 6 Westerhoff M, Tretiakova M, Hovan L et al. CD61, CD31, and CD34 improve diagnostic accuracy in gastric antral vascular ectasia and portal hypertensive gastropathy: An immunohistochemical and digital morphometric study. Am J Surg Pathol 2010; 34: 494-501
• 7 Burak KW, Lee SS, Beck PL. Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001; 49: 866-872
• 8 Saperas E, Perez Ayuso RM, Poca E et al. Increased gastric PGE2 biosynthesis in cirrhotic patients with gastric vascular ectasia. Am J Gastroenterol 1990; 85: 138-144
• 9 Hung EW, Mayes MD, Sharif R et al. Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial. J Rheumatol 2013; 40: 455-460
• 10 Ceribelli A, Cavazzana I, Airò P et al. Anti-RNA polymerase III antibodies as a risk marker for early gastric antral vascular ectasia (GAVE) in systemic sclerosis. J Rheumatol 2010; 37: 1544
• 11 Valdez BC, Henning D, Busch RK et al. A nucleolar RNA helicase recognized by autoimmune antibodies from a patient with watermelon stomach disease. Nucleic Acids Res 1996; 24: 1220-1224
• 12 Garcia MC, Zhou J, Henning D et al. Unique epitopes in RNA helicase II/Gu protein recognized by serum from a watermelon stomach patient. Mol Immunol 2000; 37: 351-359
• 13 Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther 2006; 23: 691-712
• 14 Lowes JR, Rode J. Neuroendocrine cell proliferations in gastric antral vascular ectasia. Gastroenterology 1989; 97: 207-212
• 15 Ripoll C, Garcia-Tsao G. The management of portal hypertensive gastropathy and gastric antral vascular ectasia. Dig Liver Dis 2011; 43: 345-351
• 16 Yew BS, Ng KY, Ang DS et al. Gastric antral vascular ectasia successfully controlled by argon plasma coagulation. Ann Acad Med Singapore 2007; 36: 702-703
• 17 Yusoff I, Brennan F, Ormonde D et al. Argon plasma coagulation for treatment of watermelon stomach. Endoscopy 2002; 34: 407-410
• 18 Herrera S, Bordas JM, Llach J et al. The beneficial effects of argon plasma coagulation in the management of different types of gastric vascular ectasia lesions in patients admitted for GI hemorrhage. Gastrointest Endosc 2008; 68: 440-446
• 19 Kwan V, Bourke MJ, Williams SJ et al. Argon plasma coagulation in the management of symptomatic gastrointestinal vascular lesions: experience in 100 consecutive patients with long-term follow-up. Am J Gastroenterol 2006; 101: 58-63
• 20 Chiu YC, Lu LS, Wu KL et al. Comparison of argon plasma coagulation in management of upper gastrointestinal angiodysplasia and gastric antral vascular ectasia hemorrhage. BMC Gastroenterol 2012; 12: 67
• 21 Sebastian S, McLoughlin R, Qasim A et al. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia (watermelon stomach): long-term results. Dig Liver Dis 2004; 36: 212-217
• 22 Bhatti MA, Khan AA, Alam A et al. Efficacy of argon plasma coagulation in gastric vascular ectasia in patients with liver cirrhosis. J Coll Physicians Surg Pak 2009; 19: 219-222
• 23 Lecleire S, Ben-Soussan E, Antonietti M et al. Bleeding gastric vascular ectasia treated by argon plasma coagulation: a comparison between patients with and without cirrhosis. Gastrointest Endosc 2008; 67: 219-225
• 24 Naga M, Esmat S, Naguib M et al. Long-term effect of argon plasma coagulation (APC) in the treatment of gastric antral vascular ectasia (GAVE). Arab J Gastroenterol 2011; 12: 40-43
• 25 Probst A, Scheubel R, Wienbeck M. Treatment of watermelon stomach (GAVE syndrome) by means of endoscopic argon plasma coagulation (APC): long-term outcome. Z Gastroenterol 2001; 39: 447-452
• 26 Chaves DM, Sakai P, Oliveira CV et al. Watermelon stomach: clinical aspects and treatment with argon plasma coagulation. Arq Gastroenterol 2006; 43: 191-195
• 27 Nakamura S, Mitsunaga A, Konishi H et al. Long-term follow up of gastric antral vascular ectasia treated by argon plasma coagulation. Dig Endosc 2006; 18: 128-133
• 28 Shibukawa G, Irisawa A, Sakamoto N et al. Gastric antral vascular ectasia (GAVE) associated with systemic sclerosis: relapse after endoscopic treatment by argon plasma coagulation. Intern Med 2007; 46: 279-283
• 29 Roman S, Saurin JC, Dumortier J et al. Tolerance and efficacy of argon plasma coagulation for controlling bleeding in patients with typical and atypical manifestations of watermelon stomach. Endoscopy 2003; 35: 1024-1028
• 30 Farooq FT, Wong RC, Yang P et al. Gastric outlet obstruction as a complication of argon plasma coagulation for watermelon stomach. Gastrointest Endosc 2007; 65: 1090-1092
• 31 Fuccio L, Zagari RM, Serrani M et al. Endoscopic argon plasma coagulation for the treatment of gastric antral vascular ectasia-related bleeding in patients with liver cirrhosis. Digestion 2009; 79: 143-150
• 32 Baudet JS, Salata H, Soler M et al. Hyperplastic gastric polyps after argon plasma coagulation treatment of gastric antral vascular ectasia (GAVE). Endoscopy 2007; 39: E320
• 33 Rosenfeld G, Enns R. Argon photocoagulation in the treatment of gastric antral vascular ectasia and radiation proctitis. Can J Gastroenterol 2009; 23: 801-804
• 34 Muguruma N, Okamoto K, Kimura T et al. Endoscopic ablation therapy for gastrointestinal superficial neoplasia. Dig Endosc 2012; 24: 139-149
• 35 Zhou C, Adler DC, Becker L et al. Effective treatment of chronic radiation proctitis using radiofrequency ablation. Therap Adv Gastroenterol 2009; 2: 149-156
• 36 Rustagi T, Mashimo H. Endoscopic management of chronic radiation proctitis. World J Gastroenterol 2011; 17: 4554-4562
• 37 Gross SA, Al-Haddad M, Gill KR et al. Endoscopic mucosal ablation for the treatment of gastric antral vascular ectasia with the HALO90 system: a pilot study. Gastrointest Endosc 2008; 67: 324-327
• 38 McGorisk T, Krishnan K, Keefer L et al. Radiofrequency ablation for refractory gastric antral vascular ectasia (with video). Gastrointest Endosc 2013; 78: 584-588
• 39 Dray X, Repici A, Gonzalez P et al. 1040 Radiofrequency Ablation Treatment of Gastric Antral Vascular Ectasia: Results From an International Collaborative Study. Gastrointest Endosc 2013; 77: AB180
• 40 Wells CD, Harrison ME, Gurudu SR et al. Treatment of gastric antral vascular ectasia (watermelon stomach) with endoscopic band ligation. Gastrointest Endosc 2008; 68: 231-236
• 41 Sato T, Yamazaki K, Akaike J. Endoscopic band ligation versus argon plasma coagulation for gastric antral vascular ectasia associated with liver diseases. Dig Endosc 2012; 24: 237-242
• 42 Rodriguez SA, Douglas G. American Society for Gastrointestinal Endoscopy Technology Committee. Mucosal ablation devices. Gastrointest Endosc 2008; 68: 1031-1042
• 43 Mathou NG, Lovat LB, Thorpe SM et al. Nd:YAG laser induces long-term remission in transfusion-dependent patients with watermelon stomach. Lasers Med Sci 2004; 18: 213-218
• 44 Kantsevoy SV, Cruz-Correa MR, Vaughn CA et al. Endoscopic cryotherapy for the treatment of bleeding mucosal vascular lesions of the GI tract: a pilot study. Gastrointest Endosc 2003; 57: 403-406
• 45 Cho S, Zanati S, Yong E et al. Endoscopic cryotherapy for the management of gastric antral vascular ectasia. Gastrointest Endosc 2008; 68: 895-902
• 46 Petrini Jr JL, Johnston JH. Heat probe treatment for antral vascular ectasia. Gastrointest Endosc 1989; 35: 324-328
• 47 Komiyama M, Fu K, Morimoto T et al. A novel endoscopic ablation of gastric antral vascular ectasia. World J Gastrointest Endosc 2010; 2: 298-300
• 48 Chong VH. Snare coagulation for gastric antral vascular ectasia ablation. Gastrointest Endosc 2009; 69: 1195
• 49 Okamoto T, Okayama Y, Hirai M et al. Gastric vascular ectasia treated by endoscopic mucosal resection. Dig Endosc 2002; 14: 9-11
• 50 Sherman V, Klassen DR, Feldman LS et al. Laparoscopic antrectomy: a novel approach to treating watermelon stomach. J Am Coll Surg 2003; 197: 864-867
• 51 Spahr L, Villeneuve JP, Dufresne MP et al. Gastric antral vascular ectasia in cirrhotic patients: absence of relation with portal hypertension. Gut 1999; 44: 739-742
• 52 Fuccio L, Mussetto A, Laterza L et al. Diagnosis and management of gastric antral vascular ectasia. World J Gastrointest Endosc 2013; 51: 6-13
• 53 Schulz SW, O’Brien M, Maqsood M et al. Improvement of severe systemic sclerosis-associated gastric antral vascular ectasia following immunosuppressive treatment with intravenous cyclophosphamide. J Rheumatol 2009; 36: 1653-1656
• 54 Soykan I, Toruner M, Idilman R et al. Reversal of iron deficiency anemia in a patient with gastric antral vascular ectasia treated with cyproheptadine. J Clin Gastroenterol 2003; 36: 183-184
• 55 Ge ZZ, Chen HM, Gao YJ et al. Efficacy of thalidomide for refractory gastrointestinal bleeding from vascular malformation. Gastroenterology 2011; 141: 1629-1637 e1–e4
• 56 Nardone G, Rocco A, Balzano T et al. The efficacy of octreotide therapy in chronic bleeding due to vascular abnormalities of the gastrointestinal tract. Aliment Pharmacol Ther 1999; 13: 1429-1436
• 58 Barbara G, De Giorgio R, Salvioli B et al. Unsuccessful octreotide treatment of the watermelon stomach. J Clin Gastroenterol 1998; 26: 345-346
• 57 Calam J, Walker RJ. Antral vascular lesion, achlorhydria, and chronic gastrointestinal blood loss: response to steroids. Dig Dis Sci 1980; 25: 236-239
• 59 Tran A, Villeneuve JP, Bilodeau M et al. Treatment of chronic bleeding from gastric antral vascular ectasia (GAVE) with estrogen-progesterone in cirrhotic patients: an open pilot study. Am J Gastroenterol 1999; 94: 2909-2911
• 60 Moss SF, Ghosh P, Thomas DM et al. Gastric antral vascular ectasia: maintenance treatment with oestrogen-progesterone. Gut 1992; 33: 715-717